Patents by Inventor Caitlin Stein

Caitlin Stein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity anti-CD3 antibodies, and methods for their generation and use
    Patent number: 12552863
    Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: February 17, 2026
    Assignee: ADIMAB, LLC
    Inventors: Robert Pejchal, Caitlin Stein, Julia McCreary
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20250257125
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: February 4, 2025
    Publication date: August 14, 2025
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • Antibodies Targeting ActRIIA and ActRIIB
    Publication number: 20250243286
    Abstract: The present disclosure relates to antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are improved versions of bimagrumab. Antibodies of the present invention have an improved affinity against ActRIIA, translating into improved in vitro potency and efficacy, an improved PK and PD profile and a higher stability making the antibodies suitable for s.c. administration. Optionally they carry Fc modifications making the antibodies safe for prolonged treatments.
    Type: Application
    Filed: April 14, 2025
    Publication date: July 31, 2025
    Inventors: Christian KUNZ, Amélie WIEDERKEHR, Lisa WELLINGER, Anne Laure LAINÉ, Emily RADKE, Caitlin STEIN, Arvind SIVASUBRAMANIAN
  • VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
    Publication number: 20250223379
    Abstract: Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.
    Type: Application
    Filed: January 11, 2022
    Publication date: July 10, 2025
    Inventors: Caitlin STEIN, Robert PEJCHAL, Julia MCCREARY, Kyle BARLOW, Arvind SIVASUBRAMANIAN, Michael Benjamin BATTLES
  • VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
    Publication number: 20250215082
    Abstract: Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.
    Type: Application
    Filed: January 11, 2023
    Publication date: July 3, 2025
    Inventors: Caitlin STEIN, Robert PEJCHAL, Julia MCCREARY, Kyle BARLOW, Arvind SIVASUBRAMANIAN, Michael Benjamin BATTLES, Beth H. SHARKEY
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20250215072
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: September 17, 2024
    Publication date: July 3, 2025
    Inventors: Abhishek Datta, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. Dagbay, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20250179164
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 8, 2024
    Publication date: June 5, 2025
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • Antibodies Targeting ActRIIA and ActRIIB
    Publication number: 20250109208
    Abstract: The present disclosure relates to antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are improved versions of bimagrumab. Antibodies of the present invention have an improved affinity against ActRIIA, translating into improved in vitro potency and efficacy, an improved PK and PD profile and a higher stability making the antibodies suitable for s.c. administration. Optionally they carry Fc modifications making the antibodies safe for prolonged treatments.
    Type: Application
    Filed: November 13, 2024
    Publication date: April 3, 2025
    Inventors: Christian KUNZ, Amélie WIEDERKEHR, Lisa WELLINGER, Anne Laure LAINÉ, Emily RADKE, Caitlin STEIN, Arvind SIVASUBRAMANIAN
  • Methods of screening for high-affinity, isoform-selective TGF?1 inhibitors
    Patent number: 12252531
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: March 18, 2025
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 12173059
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: December 24, 2024
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • Isoform-selective TGFB1 inhibitors and use thereof
    Patent number: 12122823
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 22, 2024
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230002487
    Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: January 5, 2023
    Inventors: Robert PEJCHAL, Caitlin STEIN, Julia McCREARY
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220363741
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 17, 2022
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11365245
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220064276
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11214614
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 4, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210340238
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 4, 2021
    Inventors: Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto